| Group comparison . | North-east (more effective but more costly) . | South-west (less effective but less costly) . | North-west (less effective but more costly, i.e. inferior) . | South-east (more effective but less costly, i.e. dominant) . |
|---|---|---|---|---|
| MS model | ||||
| GnRHa plus Chemo versus Chemo | 86.27% | 8.35% | 0.45% | 4.93% |
| Group comparison . | North-east (more effective but more costly) . | South-west (less effective but less costly) . | North-west (less effective but more costly, i.e. inferior) . | South-east (more effective but less costly, i.e. dominant) . |
|---|---|---|---|---|
| MS model | ||||
| GnRHa plus Chemo versus Chemo | 86.27% | 8.35% | 0.45% | 4.93% |
Chemo, chemotherapy; GnRHa, GnRH agonist; GnRHa plus Chemo, adding GnRHa during chemotherapy; MS, menopausal symptoms.
| Group comparison . | North-east (more effective but more costly) . | South-west (less effective but less costly) . | North-west (less effective but more costly, i.e. inferior) . | South-east (more effective but less costly, i.e. dominant) . |
|---|---|---|---|---|
| MS model | ||||
| GnRHa plus Chemo versus Chemo | 86.27% | 8.35% | 0.45% | 4.93% |
| Group comparison . | North-east (more effective but more costly) . | South-west (less effective but less costly) . | North-west (less effective but more costly, i.e. inferior) . | South-east (more effective but less costly, i.e. dominant) . |
|---|---|---|---|---|
| MS model | ||||
| GnRHa plus Chemo versus Chemo | 86.27% | 8.35% | 0.45% | 4.93% |
Chemo, chemotherapy; GnRHa, GnRH agonist; GnRHa plus Chemo, adding GnRHa during chemotherapy; MS, menopausal symptoms.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
